ATE471313T1 - 3,5-di(aryl - oder heteroaryl) isoxazole und 1,2, 4-oxadiazole als s1p1-rezeptoragonisten, das immunsystem unterdrückende und entzündungshemmende mittel - Google Patents

3,5-di(aryl - oder heteroaryl) isoxazole und 1,2, 4-oxadiazole als s1p1-rezeptoragonisten, das immunsystem unterdrückende und entzündungshemmende mittel

Info

Publication number: ATE471313T1
Authority: AT; Austria
Prior art keywords: supressive; isoxazoles; oxadiazoles; heteroaryl; aryl
Prior art date: 2006-01-27

Application number

AT07703028T

Other languages

English (en)

Inventor

Rainer Albert

Frederic Zecri

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-01-27

Filing date

2007-01-25

Publication date

2010-07-15

2007-01-25 Application filed by Novartis Ag filed Critical Novartis Ag

2010-07-15 Application granted granted Critical

2010-07-15 Publication of ATE471313T1 publication Critical patent/ATE471313T1/de

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Diabetes (AREA)
Oncology (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Neurology (AREA)
Hematology (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Obesity (AREA)
Otolaryngology (AREA)
Transplantation (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)

AT07703028T 2006-01-27 2007-01-25 3,5-di(aryl - oder heteroaryl) isoxazole und 1,2, 4-oxadiazole als s1p1-rezeptoragonisten, das immunsystem unterdrückende und entzündungshemmende mittel ATE471313T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0601744.6A GB0601744D0 (en)	2006-01-27	2006-01-27	Organic compounds
PCT/EP2007/000638 WO2007085451A2 (en)	2006-01-27	2007-01-25	3,5-di (aryl or heteroaryl) isoxazoles and 1, 2, 4-oxadiazoles as s1p1 receptor agonists, immunosuppresssive and anti -inflammatory agents

Publications (1)

Publication Number	Publication Date
ATE471313T1 true ATE471313T1 (de)	2010-07-15

Family

ID=36061049

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT07703028T ATE471313T1 (de)	2006-01-27	2007-01-25	3,5-di(aryl - oder heteroaryl) isoxazole und 1,2, 4-oxadiazole als s1p1-rezeptoragonisten, das immunsystem unterdrückende und entzündungshemmende mittel

Country Status (16)

Country	Link
US (1)	US7799812B2 (de)
EP (2)	EP2233473A1 (de)
JP (1)	JP2009524611A (de)
KR (1)	KR20080091161A (de)
CN (1)	CN101374821A (de)
AT (1)	ATE471313T1 (de)
AU (1)	AU2007209533A1 (de)
BR (1)	BRPI0707285A2 (de)
CA (1)	CA2637081A1 (de)
DE (1)	DE602007007186D1 (de)
ES (1)	ES2347015T3 (de)
GB (1)	GB0601744D0 (de)
PL (1)	PL1981858T4 (de)
PT (1)	PT1981858E (de)
RU (1)	RU2008134534A (de)
WO (1)	WO2007085451A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7241790B2 (en)	2002-07-30	2007-07-10	University Of Virginia Patent Foundation	Compounds active in spinigosine 1-phosphate signaling
US7638637B2 (en)	2003-11-03	2009-12-29	University Of Virginia Patent Foundation	Orally available sphingosine 1-phosphate receptor agonists and antagonists
WO2006010379A1 (en)	2004-07-29	2006-02-02	Actelion Pharmaceuticals Ltd.	Novel thiophene derivatives as immunosuppressive agents
US7754703B2 (en)	2005-02-14	2010-07-13	University Of Virginia Patent Foundation	Cycloalkane-containing sphingosine 1-phosphate agonists
CA2602474C (en)	2005-03-23	2014-06-10	Actelion Pharmaceuticals Ltd	Hydrogenated benzo (c) thiophene derivatives as immunomodulators
WO2006131336A1 (en) *	2005-06-08	2006-12-14	Novartis Ag	POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
AR057894A1 (es)	2005-11-23	2007-12-26	Actelion Pharmaceuticals Ltd	Derivados de tiofeno
TWI404706B (zh)	2006-01-11	2013-08-11	Actelion Pharmaceuticals Ltd	新穎噻吩衍生物
AU2007209051A1 (en)	2006-01-24	2007-08-02	Actelion Pharmaceuticals Ltd	Novel pyridine derivatives
JP2009528274A (ja)	2006-01-27	2009-08-06	ユニバーシティオブバージニアパテントファンデーション	神経因性疼痛の治療法
JP2009526073A (ja)	2006-02-09	2009-07-16	ユニバーシティオブバージニアパテントファンデーション	二環式スフィンゴシン−１−リン酸受容体アナログ
PT2069336E (pt)	2006-09-07	2013-03-07	Actelion Pharmaceuticals Ltd	Derivados de piridin-4-ilo como agentes imunomoduladores
AR061841A1 (es)	2006-09-07	2008-09-24	Actelion Pharmaceuticals Ltd	Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores.
PL2069335T3 (pl)	2006-09-08	2013-05-31	Actelion Pharmaceuticals Ltd	Pochodne pirydyn-3-ylu jako środki immunomodulujące
ES2393412T3 (es)	2006-09-21	2012-12-21	Actelion Pharmaceuticals Ltd.	Derivados de fenilo y su uso como inmunomoduladores
CA2669104A1 (en)	2006-11-21	2008-05-29	University Of Virginia Patent Foundation	Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
AU2007323557A1 (en)	2006-11-21	2008-05-29	University Of Virginia Patent Foundation	Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
JP2010510249A (ja)	2006-11-21	2010-04-02	ユニバーシティオブバージニアパテントファンデーション	スフィンゴシン＝１−燐酸アゴニスト活性を有するテトラリンアナログ
EP2109364A4 (de)	2006-12-15	2010-04-14	Abbott Lab	Neuartige oxadiazolverbindungen
JO2701B1 (en)	2006-12-21	2013-03-03	جلاكسو جروب ليميتد	Vehicles
BRPI0808789A2 (pt) *	2007-03-16	2014-08-12	Actelion Pharmaceuticals Ltd	Compostos e composição farmacêutica de derivados aminopiridina e uso destes
AU2008240773B2 (en) *	2007-04-19	2013-10-03	Glaxo Group Limited	Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists
PT2195311E (pt)	2007-08-17	2011-05-25	Actelion Pharmaceuticals Ltd	Derivados de piridina como moduladores do receptor s1p1/edg1
WO2009053481A1 (en) *	2007-10-25	2009-04-30	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Compositions and methods for modulating nk and t cell trafficking
KR20100092473A (ko) *	2007-11-01	2010-08-20	액테리온 파마슈티칼 리미티드	신규한 피리미딘 유도체
MX2010005889A (es)	2007-12-10	2010-06-22	Actelion Pharmaceuticals Ltd	Derivados de tiofeno como agonistas de s1p1/edg1.
WO2009082398A1 (en)	2007-12-21	2009-07-02	University Of Notre Dame Du Lac	Antibacterial compounds and methods of using same
WO2009109907A1 (en) *	2008-03-06	2009-09-11	Actelion Pharmaceuticals Ltd	Novel pyrimidine-pyridine derivatives
EP2262799B1 (de) *	2008-03-06	2012-07-04	Actelion Pharmaceuticals Ltd.	Pyridinverbindungen
CA2715317A1 (en)	2008-03-07	2009-09-11	Actelion Pharmaceuticals Ltd	Novel aminomethyl benzene derivatives
US8580841B2 (en)	2008-07-23	2013-11-12	Arena Pharmaceuticals, Inc.	Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
HRP20160890T1 (hr)	2008-08-27	2016-09-23	Arena Pharmaceuticals, Inc.	Derivati supstituirane tricikličke kiseline kao agonisti s1p1-receptora korisni u liječenju autoimunih i upalnih poremećaja
EP2210890A1 (de) *	2009-01-19	2010-07-28	Almirall, S.A.	Oxadiazol Derivate als S1P1 Rezeptor Agonisten
JP2012515787A (ja)	2009-01-23	2012-07-12	ブリストル−マイヤーズスクイブカンパニー	自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体
ES2405054T3 (es)	2009-01-23	2013-05-30	Bristol-Myers Squibb Company	Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato
WO2010085582A1 (en)	2009-01-23	2010-07-29	Bristol-Myers Squibb Company	Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
CA2767585C (en)	2009-07-16	2017-09-26	Actelion Pharmaceuticals Ltd	Pyridin-4-yl derivatives
US8399451B2 (en)	2009-08-07	2013-03-19	Bristol-Myers Squibb Company	Heterocyclic compounds
JP5856980B2 (ja)	2010-01-27	2016-02-10	アリーナファーマシューティカルズ，インコーポレイテッド	（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
CN105503882B (zh)	2010-03-03	2019-07-05	艾尼纳制药公司	制备s1p1受体调节剂及其晶体形式的方法
US8273776B2 (en) *	2010-04-16	2012-09-25	Allergan, Inc	Biphenyl oxadiazole derivatives as sphingosine-1-phosphate receptors modulators
ES2548683T3 (es)	2010-04-23	2015-10-20	Bristol-Myers Squibb Company	Amidas del ácido 4-(5-isoxazolil o 5-pirrazolil-1,2,4-oxadiazol-3-il)-mandélico como agonistas de receptor de esfingosina-1-fosfato 1
TW201206429A (en) *	2010-07-08	2012-02-16	Merck Serono Sa	Substituted oxadiazole derivatives
US8822510B2 (en)	2010-07-20	2014-09-02	Bristol-Myers Squibb Company	Substituted 3-phenyl-1,2,4-Oxadiazole compounds
EP2619190B1 (de)	2010-09-24	2015-08-12	Bristol-Myers Squibb Company	Substituierte oxadiazolverbindungen und ihre verwendung als s1p1-agonisten
MA34910B1 (fr)	2011-01-19	2014-02-01	Actelion Pharmaceuticals Ltd	Dérivés de 2-methoxy-pyridin-4-yl
EP2570404A1 (de) *	2011-09-16	2013-03-20	Syngenta Participations AG.	Verbindungen zur Regulierung des Pflanzenwachstums
EP2867230B1 (de)	2012-07-02	2020-02-12	Monsanto Technology LLC	Verfahren zur herstellung von 3,5-disubstituierten 1,2,4-oxadiazolen
AU2015319834A1 (en)	2014-09-25	2017-04-20	University Of Notre Dame Du Lac	Non-beta lactam antibiotics
PL3242666T3 (pl)	2015-01-06	2025-02-17	Arena Pharmaceuticals, Inc.	Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
PH12017502097B1 (en)	2015-05-20	2023-05-05	Idorsia Pharmaceuticals Ltd	Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
BR112017027656B1 (pt)	2015-06-22	2023-12-05	Arena Pharmaceuticals, Inc.	Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
WO2018049404A1 (en)	2016-09-12	2018-03-15	University Of Notre Dame Du Lac	Compounds for the treatment of clostridium difficile infection
MX2019009841A (es)	2017-02-16	2020-01-30	Arena Pharm Inc	Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
MX2019009843A (es)	2017-02-16	2020-01-30	Arena Pharm Inc	Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales.
CA3102136A1 (en)	2018-06-06	2019-12-12	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the s1p1 receptor
CN112955431A (zh)	2018-09-06	2021-06-11	艾尼纳制药公司	可用于治疗自身免疫性病症和炎性病症的化合物
EP4126829B1 (de)	2020-03-27	2026-02-18	Receptos LLC	Sphingosin-1-phosphatrezeptormodulatoren
CN111518091B (zh) *	2020-04-22	2023-02-03	安徽医科大学	一种1，2，4-噁二唑并吡啶类化合物ahmu07及其作为抗菌药物的应用
CN119968367A (zh) *	2022-08-01	2025-05-09	韩国科学技术研究院	新型杂环基苯基甲胺衍生物、制备方法及其预防、缓解或治疗多发性硬化症的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU5647099A (en) *	1998-09-11	2000-04-03	Shionogi & Co., Ltd.	Remedal or preventive agent for congestive heart failure
DE19904389A1 (de) *	1999-02-04	2000-08-10	Bayer Ag	Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe
CN1199956C (zh) *	2000-04-21	2005-05-04	盐野义制药株式会社	具有抗癌作用的噁二唑衍生物
WO2001083464A1 (en) *	2000-04-21	2001-11-08	Shionogi & Co., Ltd.	Oxadiazole derivatives having therapeutic or preventive efficacies against glomerular disorders
EP2070921A1 (de)	2000-11-07	2009-06-17	Novartis Ag	Indolylmaleinimid-Derivate als Proteinkinase-C-Inhibitoren
EP1405636A4 (de) *	2001-06-26	2009-04-15	Takeda Pharmaceutical	Funktionsregler für retinoid-relativ-rezeptor
WO2003035610A1 (en)	2001-10-26	2003-05-01	Shionogi & Co., Ltd.	Sulfonamide derivative having mmp inhibitory activity
US20050227994A1 (en) *	2002-03-27	2005-10-13	Shionogi & Co., Ltd.	Decomposition inhibitor for extracellular matrix of cartilage
TW200918046A (en)	2002-04-03	2009-05-01	Novartis Ag	Indolylmaleimide derivatives
CA2506432A1 (en)	2002-12-09	2004-06-24	Robert A. Kirken	Methods for selectively inhibiting janus tyrosine kinase 3 (jak3)
AU2004240586A1 (en)	2003-05-15	2004-12-02	Merck & Co., Inc.	3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists
EP1644367B1 (de) *	2003-05-19	2015-10-14	Novartis AG	Die immunreaktion unterdrückende verbindungen und zusammensetzungen
EP1650199A4 (de) *	2003-07-30	2008-11-19	Shionogi & Co	Sulfonamidderivat mit isoxazolring
US20070043014A1 (en) *	2003-10-01	2007-02-22	Merck & Co., Inc.	3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
EP1697333A4 (de) *	2003-12-17	2009-07-08	Merck & Co Inc	(3,4-disubstituierte)propansäurecarboxylate als agonisten des s1p (edg) rezeptors
DK1704145T3 (da)	2004-01-12	2012-09-24	Ym Biosciences Australia Pty	Selektive kinaseinhibitorer
TW200538433A (en) *	2004-02-24	2005-12-01	Irm Llc	Immunosuppressant compounds and compositiions
WO2006131336A1 (en) *	2005-06-08	2006-12-14	Novartis Ag	POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS

2006
- 2006-01-27 GB GBGB0601744.6A patent/GB0601744D0/en not_active Ceased
2007
- 2007-01-25 BR BRPI0707285-6A patent/BRPI0707285A2/pt not_active IP Right Cessation
- 2007-01-25 DE DE602007007186T patent/DE602007007186D1/de active Active
- 2007-01-25 JP JP2008551722A patent/JP2009524611A/ja active Pending
- 2007-01-25 AU AU2007209533A patent/AU2007209533A1/en not_active Abandoned
- 2007-01-25 CA CA002637081A patent/CA2637081A1/en not_active Abandoned
- 2007-01-25 AT AT07703028T patent/ATE471313T1/de active
- 2007-01-25 PT PT07703028T patent/PT1981858E/pt unknown
- 2007-01-25 WO PCT/EP2007/000638 patent/WO2007085451A2/en not_active Ceased
- 2007-01-25 US US12/162,413 patent/US7799812B2/en not_active Expired - Fee Related
- 2007-01-25 PL PL07703028T patent/PL1981858T4/pl unknown
- 2007-01-25 ES ES07703028T patent/ES2347015T3/es active Active
- 2007-01-25 CN CNA2007800036158A patent/CN101374821A/zh active Pending
- 2007-01-25 RU RU2008134534/04A patent/RU2008134534A/ru not_active Application Discontinuation
- 2007-01-25 EP EP10005624A patent/EP2233473A1/de not_active Withdrawn
- 2007-01-25 EP EP07703028A patent/EP1981858B1/de not_active Not-in-force
- 2007-01-25 KR KR1020087018321A patent/KR20080091161A/ko not_active Withdrawn

Also Published As

Publication number	Publication date
CN101374821A (zh)	2009-02-25
EP2233473A1 (de)	2010-09-29
PL1981858T3 (pl)	2010-12-31
US20090137636A1 (en)	2009-05-28
EP1981858B1 (de)	2010-06-16
JP2009524611A (ja)	2009-07-02
WO2007085451A3 (en)	2007-12-21
WO2007085451A2 (en)	2007-08-02
CA2637081A1 (en)	2007-08-02
KR20080091161A (ko)	2008-10-09
ES2347015T3 (es)	2010-10-22
PT1981858E (pt)	2010-09-07
DE602007007186D1 (de)	2010-07-29
RU2008134534A (ru)	2010-03-10
EP1981858A2 (de)	2008-10-22
US7799812B2 (en)	2010-09-21
GB0601744D0 (en)	2006-03-08
PL1981858T4 (pl)	2010-12-31
BRPI0707285A2 (pt)	2011-04-26
AU2007209533A1 (en)	2007-08-02

Legal Events

Date

Code

Title

Description

2010-12-15

UEP

Publication of translation of european patent specification

Ref document number: 1981858

Country of ref document: EP

Publication	Publication Date	Title
ATE471313T1 (de)	2010-07-15	3,5-di(aryl - oder heteroaryl) isoxazole und 1,2, 4-oxadiazole als s1p1-rezeptoragonisten, das immunsystem unterdrückende und entzündungshemmende mittel
NO20074592L (no)	2007-10-19	Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
ATE526318T1 (de)	2011-10-15	Farnesoid-x-rezeptor-agonisten
NO20085067L (no)	2009-02-06	4,5-difenyl-pyrimidinyl substituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
PE20090290A1 (es)	2009-04-09	Derivados de pirrolopiridina como inhibidores de bace
NO20092314L (no)	2009-08-31	Benzamidderivater som EP4 receptoragonister
DE602007009420D1 (de)	2010-11-04	Oxadiazolderivate als s1p1-rezeptor-agonisten
WO2009137391A3 (en)	2009-12-30	Benzene sulfonamide thiazole and oxazole compounds
BR112014012878A8 (pt)	2021-06-15	composto, uso de um composto, composição farmacêutica e processos de fabricação de um composto
NO20084049L (no)	2008-10-20	Forbindelser med forsterket ampa receptor og anvendelse derav i medisin
NO20091893L (no)	2009-07-09	Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav.
MA32175B1 (fr)	2011-03-01	Oxadiazoanthracènes pour le traitement du diabète
EA201001205A1 (ru)	2011-04-29	Соединения, содержащие циклобутоксигруппу
NO20083909L (no)	2008-12-15	Bisykliske benzimidazolforbindelser, og deres anvendelse som metabotropiske glutamatreseptorforsterkere
JO2793B1 (en)	2014-03-15	New Crystaline form V of Agomelatine, A process for It's Preparation and Pharmaceutical Compositions Containig it.
EA201001855A1 (ru)	2011-08-30	Соединения, содержащие циклобутоксигруппу
HRP20080552A2 (hr)	2009-03-31	Derivat benzidimazola i njegova uporaba
NO20091830L (no)	2009-07-06	Spiro-piperidinderivater som VIa reseptorantagonister
BR112014009288A2 (pt)	2017-06-13	formas sólidas de 1,l-dioxo-4-tiomorfolinil)-[6-[[3(4-fluorofenil)-5-metil-4-isoxazolil]metóxi]-3-piridinil]-metanona
MXPA03000153A (es)	2004-09-13	Nuevos derivados de tetrazol.
CL2013000027A1 (es)	2013-03-08	Compuestos derivados de (3-(4-(aminometil)fenoxi o feniltio)azetidin-1-il)(5-fenil-1,3,4-oxadiazol-2-il)metanona, antagonistas del receptor mch1; proceso para prepararlos; composicion farmaceutica; metodo de tratamiento; compuesto intermediario; y su uso para el tratamiento o profilaxis de la obesisdad.
NO20060969L (no)	2006-04-11	Benzoxazinon avledende sulfonamid forbindelser, deres fremstilling og anvedelse som medikamenter
NO20073295L (no)	2008-01-02	Nye naftalenforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
DE602005014629D1 (de)	2009-07-09	Pyrazolphenylderivate als ppar-aktivatoren
CL2008003758A1 (es)	2009-08-07	Compuestos derivados de 1(2)h-tetrazol-5-il-fenil-oxazolidinonas, procedimiento de preparacion, composicion farmaceutica, util para el tratamiento de infecciones bacterianas.